Day: March 17, 2025
Precision BioSciences Announces Clearance of Investigational New Drug Application by the U.S. FDA for First-in-Class PBGENE-HBV Designed to Eliminate Root Cause of Chronic Hepatitis B
- PBGENE-HBV is the first-ever investigational in vivo gene editing therapy cleared to enter clinical trials for the treatment of chronic hepatitis B in the United States ( U.S. ) – - IND clearance represents a significant regulatory milestone for PBGENE-HBV – - Company to expand its Phase 1